News Release Details

Back to News

Arcutis to Report Fourth Quarter 2022 Financial Results and Participate in Upcoming Investor Conference

February 8, 2023 at 8:01 AM EST
  • Quarterly investor conference call and webcast scheduled for Tuesday, February 28 at 4:30 p.m. ET
  • Arcutis management will also participate in the Cowen 43rd Annual Healthcare Conference in March

WESTLAKE VILLAGE, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced that it will host a conference call and webcast at 4:30 p.m. ET on Tuesday, February 28, 2022 to report its fourth quarter and full year financial results, and provide a business update.

A live webcast of the call and the presentation material will be available on the “Events” section of the Company’s investor website. An archived replay of the webcast will be available on the Arcutis investor website following the conference.

Arcutis also announced its participation for an upcoming investor conference. Details for the company’s participation are as follows:

  • Cowen 43rd Annual Health Care Conference
    Fireside Chat Date/Time: Tuesday, March 7 at 10:30 a.m. ET
    Dermatology Panel Discussion Date/Time: Tuesday, March 7 at 12:50 p.m. ET

A live webcast for each of these events may be accessed at the “Events” section of the Company’s website.

About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio that harnesses our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, seborrheic dermatitis, and alopecia areata. For more information, visit or follow Arcutis on LinkedIn, Facebook, and Twitter.

Forward-Looking Statements
This press release contains "forward-looking" statements. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the "Risk Factors" section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 22, 2022, as amended on March 3, 2022, as well as any subsequent filings with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.


Amanda Sheldon, Head of Corporate Communications

Eric McIntyre, Head of Investor Relations